Clinical Trials Logo

Multiple Myeloma clinical trials

View clinical trials related to Multiple Myeloma.

Filter by:

NCT ID: NCT03952832 Not yet recruiting - Clinical trials for Smoldering Plasma Cell Myeloma

Leflunomide in Treating Patients With High-Risk Smoldering Multiple Myeloma

Start date: June 11, 2019
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well leflunomide works in treating patients with high-risk smoldering multiple myeloma. Leflunomide may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT03952091 Recruiting - Clinical trials for Refractory Multiple Myeloma

TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Start date: March 27, 2019
Phase: Phase 3
Study type: Interventional

A phase 3, randomized, open-label, parallel-controlled, multi-center study comparing TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in subjects with relapsed or refractory multiple myeloma who received at least 1 prior line of treatment

NCT ID: NCT03951220 Recruiting - Myeloma Clinical Trials

The Development and Pilot Testing of a New MR Imaging Protocol to Quantify Myeloma Disease Burden and Bone Loss

LOOMIS
Start date: March 29, 2018
Phase:
Study type: Observational

In the proposed study, the investigators will aim to develop and pilot a Magnetic Resonance (MR) imaging protocol and assess its ability to achieve the following: quantification of tumour burden and bone loss, detecting longitudinal changes in tumour load with therapy and detecting longitudinal changes in microarchitecture with therapy. The investigators also aim to investigate whether bone loss is better, worse or the same with different imaging techniques. This will be investigated by correlating the DXA imaging data with Diffusion-Weighted Magnetic Resonance Imaging (DWMRI) to see if it is possible to achieve quantifiable data of bone density.

NCT ID: NCT03948035 Recruiting - Clinical trials for Newly Diagnosed Multiple Myeloma

Elotuzumab in Combination With Carfilzomib, Lenalidomide and Dexamethasone (E-KRd) Versus KRd in MM

Start date: August 28, 2018
Phase: Phase 3
Study type: Interventional

Of the next-generation compounds, the monoclonal antibodies (moAbs) have recently attracted a lot of interest in MM. The anti-SLAMF7 directed moAb elotuzumab has completed phase III trials in MM patients. One phase III trial in MM patients with one to three prior lines of therapy compared elotuzumab-Rd with standard Rd. The triple combination was shown to significantly prolong PFS in this patient cohort with a greater proportion of patients in at least very good partial response (VGPR) when compared to subjects on Rd. Notably, the rate of infusion-related reactions with this specific moAb was very low, with an overall rate of 10% in premedicated patients and only 1% of Grade 3 severity. Grades 4/5 infusion-related reactions were absent and only 1% of patients on elotuzumab discontinued for infusion-related reactions. Of particular interest is the observation in this trial, that response and PFS were independent of cytogenetic high-risk features, i.e., deletion of chromosome 17p and translocation t(4;14). This effect distinguishes elotuzumab from most, if not all, other drug-based approaches. The investigators assume that incorporating the moAb into the KRd triple induction regimen should result in an even higher rate of deep (negative for MRD in conjunction with at least very good partial response [VGPR] as defined by the International Myeloma Working Group [IMWG]) with these responses occurring independently of cytogenetic risk. Due to potential interference of elotuzumab with serum immune fixation, the investigators chose VGPR rather than complete response (CR) to exclude false-positive immunofixation results. Furthermore the investigators hypothesize that combining elotuzumab with lenalidomide should prolong PFS further.

NCT ID: NCT03946332 Not yet recruiting - Multiple Myeloma Clinical Trials

Physical Activity for Myeloma Autograft Longitudinal Study

PAMAL
Start date: May 2019
Phase: N/A
Study type: Interventional

Physical exercises program is known to improve quality of life, chronical fatigue and appears to be a behavioural recommendation against cancer as primary and tertiary prevention. Nutritional status is also important in cancer patients: a loss of 5% of weight increases the complication risks and decreases survival and the quality of life. Interactions between physical activity and haematological malignancies are less described compared to solid cancers. Methodology and protocols are also heterogeneous. Supervised exercises program improves the physical condition and the quality of life; however there are few randomised studies versus a controlled group. Post autograft evaluation for myeloma patients showed a physical deficit with increased fat mass, but in this particular population physical exercises need to be more explored. This project is a randomised study versus controlled group that evaluates supervised physical exercises program in a homogenous population: patients under-65-years-old with multiple myeloma and who will undergo autologous stem cell transplantation.

NCT ID: NCT03944057 Not yet recruiting - Clinical trials for Multiple Myeloma in Relapse

A Study of Evaluating the Safety and Efficacy of ATG-010 in Relapsed Refractory Multiple Myeloma

MARCH
Start date: June 1, 2019
Phase: Phase 2
Study type: Interventional

This is an open-label, single-arm study of ATG-010 (selinexor) plus low-dose Dexamethasone (Sd) in patients with multiple myeloma previously treated with lenalidomide and bortezomib refractory to prior treatment with immunomodulatory agents and proteasome Inhibitors.

NCT ID: NCT03943472 Not yet recruiting - Multiple Myeloma Clinical Trials

BCMA Chimeric Antigen Receptor Expressing T Cells Therapy for Relapsed/Refractory Multiple Myeloma

Start date: May 2019
Phase: Early Phase 1
Study type: Interventional

The goal of this clinical trial is to study the feasibility and efficacy of anti-B-Cell Maturation Antigen (BCMA) expressing T cells in treating patients with multiple myeloma.

NCT ID: NCT03942224 Not yet recruiting - Plasma Cell Myeloma Clinical Trials

Daratumumab, Ixazomib, & Dexamethasone With or Without Bortezomib in Patients With Newly Diagnosed Multiple Myeloma

DeRIVE
Start date: May 1, 2020
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well daratumumab, ixazomib, and dexamethasone with or without bortezomib work in treating patients with newly diagnosed multiple myeloma. Immunotherapy with monoclonal antibodies, such as daratumumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as ixazomib, dexamethasone, and bortezomib, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving daratumumab, ixazomib, and dexamethasone with or without bortezomib may work better in treating patients with multiple myeloma.

NCT ID: NCT03941860 Not yet recruiting - Plasma Cell Myeloma Clinical Trials

Lenalidomide With or Without Ixazomib in Treating Patients With Evidence of Residual Multiple Myeloma After Stem Cell Transplant

Start date: May 29, 2019
Phase: Phase 3
Study type: Interventional

This phase III trial studies how well lenalidomide in combination with ixazomib works compared to lenalidomide alone in treating patients with evidence of residual multiple myeloma after stem cell transplant. Immunotherapy with lenalidomide may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Ixazomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving lenalidomide and ixazomib together may work better than giving lenalidomide alone in treating patients with evidence of residual multiple myeloma after a stem cell transplant.

NCT ID: NCT03940833 Recruiting - Multiple Myeloma Clinical Trials

Clinical Research of Adoptive BCMA CAR-NK Cells on Relapse/Refractory MM

Start date: May 2019
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to infuse BCMA CAR-NK 92 cells to the patients with relapsed and refractory multiple myeloma (MM), to assess the safety and feasibility of this strategy. The CAR enables the NK-92 cells to recognize and kill the MM cells by targeting of BCMA, a protein expressed of the surface of the malignant plasma cells in MM patients.